To The Moon

$Invesco QQQ(QQQ)$ $SPDR S&P 500 ETF Trust(SPY)$ Volatility is tightening, which could hint at a bullish diamond continuation pattern forming around a key pivot level.

$SPDR S&P 500 ETF Trust(SPY)$  $Capital One(COF)$ The stock had a very clean open and close above the 200 level. That's exactly what you want to see as earnings approach. I've always liked this one. They also give me 3% back on all my grocery purchases, which I consistently redeem as cash against my charges.

$iShares MSCI South Korea ETF(EWY)$ $Direxion Daily MSCI South Korea Bull 3x Shares(KORU)$ $SPDR S&P 500 ETF Trust(SPY)$ Looks like it could be time for a rally.

$SPDR S&P 500 ETF Trust(SPY)$  I'm not really worried about a bubble here, honestly. I just don't see it popping.

$SPDR S&P 500 ETF Trust(SPY)$ How much is this code worth? This was for SPY. Precision hits.

$SPDR S&P 500 ETF Trust(SPY)$  Sometimes the best approach with a trade is to just wait for your thesis to play out. I'm not giving up on my view on BABA.

$Figma(FIG)$  Figma looks to be in a squeeze situation at the moment.

$SPDR S&P 500 ETF Trust(SPY)$ Another all-time high to close out the week.

July 01 Trade Idea shared 9:31 AM ET. SPX 7530/35 Call Credit Spread (0DTE) - Successful. Reached +50% of Max Profit by 9:45 AM ET first from 0.45c high. Reached Max Profit Levels by 2:15 PM ET from 1.65c highest. Expiring at Max Profit as index was cleanly contained at HOD within Hedge Zone then breaking back below it into pivotal 7460-80 zone by Expiry. $SPDR S&P 500 ETF Trust(SPY)$  SPX $Eversource(ES)$ _F $Cboe Volatility Index(VIX)$  STUDY

$SELLAS Life Sciences Group Inc.(SLS)$ It's July, and we're still waiting for the 80th event. Most people see a delay. I see what happens when an immunotherapy keeps patients alive long enough that events stop occurring on schedule. GPS isn't CAR-T. It doesn't engineer cells—it trains your own immune system to recognize WT1 and keeps expanding T-cell responses over time. That's exactly why the FDA approved unlimited dosing in REGAL. No 80th event. Unlimited dosing. Growing immunotherapy spotlight. Change-in-control filings. The pieces keep lining up. If patients weren't living longer, this trial would've been over months ago. The delay isn't the story... the data is.